Evidence gaps and route-dependent development requirements for CAR cellular therapy in urothelial carcinoma: a systematic evidence map and public-data analysis
BackgroundChimeric antigen receptor (CAR)-engineered cells are being investigated for urothelial carcinoma, but evidence requirements for antigen selection and local or systemic delivery remain undefined. We asked whether any target or route can presen…